{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:57:32Z","timestamp":1760061452548},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"crossref","award":["15\/477"],"award-info":[{"award-number":["15\/477"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fred Fastier Trust"},{"DOI":"10.13039\/100008247","name":"University of Otago","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008247","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.jpba.2016.11.046","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T16:16:01Z","timestamp":1480090561000},"page":"133-139","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis"],"prefix":"10.1016","volume":"135","author":[{"given":"Mohammad A.M.","family":"Momin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sim J.","family":"Thien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woravimol","family":"Krittaphol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyamal C.","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2016.11.046_bib0005","series-title":"Global Tuberculosis Report 2015","year":"2015"},{"key":"10.1016\/j.jpba.2016.11.046_bib0010","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1128\/AAC.02346-12","article-title":"Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis","volume":"57","author":"Dharmadhikari","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2016.11.046_bib0015","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1128\/AAC.00074-08","article-title":"Powerful bactericidal and sterilizing activity of a regimen containing PA-824 moxifloxacin, and pyrazinamide in a murine model of tuberculosis","volume":"52","author":"Nuermberger","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2016.11.046_bib0020","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","article-title":"14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial","volume":"380","author":"Diacon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2016.11.046_bib0025","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/13543784.2013.801958","article-title":"PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis","volume":"22","author":"Dawson","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jpba.2016.11.046_bib0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijpharm.2014.12.009","article-title":"Pulmonary drug delivery systems for tuberculosis treatment","volume":"478","author":"Pham","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2016.11.046_bib0035","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1128\/AAC.01389-08","article-title":"Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation","volume":"53","author":"Sung","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2016.11.046_bib0040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jpba.2006.06.026","article-title":"High-performance liquid chromatography assay for moxifloxacin: pharmacokinetics in human plasma","volume":"43","author":"Ulu","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.11.046_bib0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jchromb.2006.07.001","article-title":"Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma","volume":"844","author":"Laban-Djurdjevi\u0107","year":"2006","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2016.11.046_bib0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0378-4347(00)00166-3","article-title":"Determination of moxifloxacin (BAY 12\u20138039) in plasma and lung tissue by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method with a new polymeric cartridge","volume":"742","author":"Lemoine","year":"2000","journal-title":"J. Chromatogr. B: Biomed. Sci. Appl."},{"key":"10.1016\/j.jpba.2016.11.046_bib0055","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0731-7085(02)00393-X","article-title":"Determination of moxifloxacin in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry","volume":"30","author":"Vishwanathan","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.11.046_bib0060","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0731-7085(99)00072-2","article-title":"Simultaneous determination of rifampicin, isoniazid and pyrazinamide in tablet preparations by multivariate spectrophotometric calibration","volume":"20","author":"Goicoechea","year":"1999","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.11.046_bib0065","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/jac\/dkl231","article-title":"A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide","volume":"58","author":"Martin","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2016.11.046_bib0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0378-4347(97)00175-8","article-title":"Determination of pyrazinamide and its main metabolites in rat urine by high-performance liquid chromatography","volume":"695","author":"Mehmedagic","year":"1997","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.jpba.2016.11.046_bib0075","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0378-4347(97)00519-7","article-title":"Quantification of pyrazinamide and its metabolites in plasma by ionic-pair high-performance liquid chromatography: implications for the separation mechanism","volume":"706","author":"Kraemer","year":"1998","journal-title":"J. Chromatogr. B: Biomed. Sci. Appl."},{"key":"10.1016\/j.jpba.2016.11.046_bib0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0021-9673(01)89427-9","article-title":"Determination of 2-methylpyrazine and pyrazinamide in reaction mixtures by gas and high-performance liquid chromatography","volume":"513","author":"Husain","year":"1990","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2016.11.046_bib0085","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/jssc.200700537","article-title":"Validation of an ultra\u2010fast UPLC\u2010UV method for the separation of antituberculosis tablets","volume":"31","author":"Nguyen","year":"2008","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2016.11.046_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2014.03.046","article-title":"LC\u2013MS\/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study","volume":"97","author":"Wang","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.11.046_bib0095","series-title":"HPLC Made to Measure: A Practical Handbook for Optimisation","author":"Kromidas","year":"2006"},{"key":"10.1016\/j.jpba.2016.11.046_bib0100","series-title":"Validation of Analytical Procedures: Text and Methodology, Q2 (R1)","author":"Guideline","year":"2005"},{"key":"10.1016\/j.jpba.2016.11.046_bib0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4172\/2153-2435.1000109","article-title":"Method development and validation for estimation of moxifloxacin HCl in tablet dosage form by RP-HPLC method","volume":"1","author":"Subbaiah","year":"2010","journal-title":"Pharm. Anal. Acta"},{"key":"10.1016\/j.jpba.2016.11.046_bib0110","volume":"Vol. III","year":"2007"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516312304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516312304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T06:56:08Z","timestamp":1536216968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708516312304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":22,"alternative-id":["S0731708516312304"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2016.11.046","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2016.11.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}